A practical reference on clinical development: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-19 and is reviewed periodically as new material appears.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
=== Missing and identification === According to UNICEF, the standard system for identifying, documenting, tracing and reuniting children with relatives or siblings was barely functional in early December 2023. Additional difficulties arose from the intensity of the fighting and the rapidly changing conditions in Gaza, which hindered efforts to communicate with hospitals and medical staff. Four months into the conflict, the UN estimated that about 40% of all people in Gaza had lost identification cards and documents due to the war, making it more difficult to identify unaccompanied children and reunite them with their families. Humanitarian organizations also reported difficulties with orphaned children who were too young to know their own names. A UNICEF spokesman said: "The youngest ones very often cannot say their name and even the older ones are usually in shock so it can be extremely difficult to identify them". Hospital and emergency workers in Gaza noted that parents and relatives of some children wrote on children's bodies, mostly on their legs and abdomens, so the children would be identifiable if found in the rubble or get lost. One employee stated: "Many of the children are missing, many get here with their skulls broken… and it’s impossible to identify them, only through that writing do they get identified." In June 2024, Save the Children stated approximately 21,000 children were missing in Gaza, including 4,000 children believed to be buried under rubble. The bodies of some of these children remained unrecovered.
For cases of recurrent pericardial effusion, an operation to create a hole between the pericardial and pleural spaces can be performed, known as a pericardial window or pericardiostomy. The congenital absence of pericardium is rare. When it happens, it usually occurs on the left side. Those affected usually do not have any symptoms and they are usually discovered incidentally. About 30 to 50 percent of the affected people have other heart abnormalities such as atrial septal defect, patent ductus arteriosus, bicuspid aortic valve, and lung abnormalities. On chest X–ray, the heart looks posteriorly rotated. Another feature is the sharp delineation of pulmonary artery and transverse aorta due to lung deposition between these two structures. If there is partial absence of pericardium, there will be bulge of the left atrial appendage. On CT and MRI scans, similar findings as chest X–ray can be shown. The left sided partial pericardium defect is difficult to see because even a normal pericardium is difficult to be seen on CT and MRI. A complete pericardial defect will show the heart displaced to the left with part of the lungs squeezed between inferior border of heart and diaphragm.
== History == It is commonly stated that the modern e-cigarette was patented in 2003 by Chinese pharmacist Hon Lik, but tobacco companies had been developing nicotine aerosol generation devices since as early as 1963.
Sources: en.wikipedia.org
The data is from the year ending January 2, and market value is from March 11, 2011. In 2014, the chain was purchased by a foreign company, Brazilian firm 3G Capital, known for its ownership of Burger King. Despite foreign ownership, Tim Hortons remains a Canadian cultural phenomenon.
Belize was granted independence on 21 September 1981. Guatemala refused to recognize the new nation because of its longstanding territorial dispute, claiming that Belize belonged to Guatemala. After independence about 1,500 British troops remained in Belize to deter any possible Guatemalan incursions. With George Cadle Price at the helm, the PUP won all national elections until 1984. In that election, the first national election after independence, the PUP was defeated by the United Democratic Party (UDP). UDP leader Manuel Esquivel replaced Price as prime minister, with Price himself unexpectedly losing his own House seat to a UDP challenger. The PUP under Price returned to power after elections in 1989. The following year the United Kingdom announced that it would end its military involvement in Belize, and the RAF Harrier detachment was withdrawn the same year, having remained stationed in the country continuously since its deployment had become permanent there in 1980. British soldiers were withdrawn in 1994, but the United Kingdom left behind a military training unit to assist with the newly created Belize Defence Force. The UDP regained power in the 1993 national election, and Esquivel became prime minister for a second time. Soon afterwards, Esquivel announced the suspension of a pact reached with Guatemala during Price's tenure, claiming Price had made too many concessions to gain Guatemalan recognition. The pact may have curtailed the 130-year-old border dispute between the two countries.
== Markers == Myoepithelial cells are true epithelial cells positive for keratins, not to be confused with myofibroblasts which are true mesenchymal cells positive for vimentin. These cells are generally positive for alpha smooth muscle actin (αSMA), cytokeratin 5/6 and other high molecular weight cytokeratins, p63 and caldesmon. Myoepithelial cells are stellate in shape and are also known as basket cells. They lie between the basement membrane and glandular epithelium. Each cell consists of a cell body from which 4-8 processes radiate and embrace the secretory unit. Myoepithelial cells have contractile functions. They help in expelling secretions from the lumen of secretory units and facilitate the movement of saliva in salivary ducts.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.